Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $43.33.

A number of research analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Citigroup reduced their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, November 27th. Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, December 20th.

Arrowhead Pharmaceuticals Trading Down 6.4 %

Shares of ARWR stock opened at $18.49 on Friday. The stock’s fifty day moving average is $21.05 and its two-hundred day moving average is $22.53. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market capitalization of $2.30 billion, a P/E ratio of -3.68 and a beta of 0.97. Arrowhead Pharmaceuticals has a fifty-two week low of $17.05 and a fifty-two week high of $39.54.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $19.59, for a total value of $246,109.17. Following the completion of the transaction, the chief executive officer now owns 3,775,772 shares of the company’s stock, valued at $73,967,373.48. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,473 shares of company stock valued at $2,937,847 in the last three months. 4.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 11.5% during the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock worth $2,401,000 after purchasing an additional 12,706 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $659,000. Erste Asset Management GmbH purchased a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $924,000. Finally, Millennium Management LLC lifted its stake in Arrowhead Pharmaceuticals by 61.9% during the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after purchasing an additional 202,280 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.